Mackie Barch - Pharmagen Founder and Vice Chairman
Chairman
Mr. Mackie A. Barch is Vice Chairman of the Board, Founder of Pharmagen, Inc. He is our President, Chief Executive Officer, Secretary, a director, and cofounder of Healthcare Distribution Specialists, now known as Pharmagen Distribution, LLC, which is our whollyowned subsidiary. Before launching Pharmagen Distribution, Mr. Barch cofounded Global Nutritional Research LLC in July 2007, which manufactures OTC products for a specific disease based on RxOTC interaction, and continues to work with GNR but GNR currently has de minis assets and operations. We have, in the past, purchased products from GNR, and may continue to do so in the future. Prior to founding Pharmagen Distribution and GNR, from late 2006 to 2007, Mr. Barch was involved in numerous financial and operational aspects of Global Pharmaceutical Sourcing . Prior to working for GPS, Mr. Barch was employed as Assistant Vice President in institutional equities at Friedman, Billings, Ramsey, an investment bank and brokerdealer, from 2001 to 2006. During his career, Mr. Barch has participated in numerous equity offerings. Mr. Barch graduated the University of ColoradoBoulder with a BA in Economics. Mr. Barch is currently an elected official in the State of Maryland, serving as a City Council Member in Kensington, MD, and was since his election in 2009. The Company determined that Mr. Barchs background with Pharmagen Distribution and in the pharmaceutical and finance industries made him the ideal candidate for appointment to the board of directors and as an officer of the Company since 2014.
| Age | 50 |
| Tenure | 11 years |
| Phone | 204-898-8160 |
| Web | https://www.pharmageninc.com |
Pharmagen Management Efficiency
The company has return on total asset (ROA) of (0.5891) % which means that it has lost $0.5891 on every $100 spent on assets. This is way below average. Pharmagen's management efficiency ratios could be used to measure how well Pharmagen manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Asset | -0.59 |
Pharmagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharmagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.59 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 5.93 M | ||||
| Shares Outstanding | 517.08 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.08 X | ||||
| Revenue | 4.81 M | ||||
| Gross Profit | 2.75 M | ||||
| EBITDA | (2.13 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.